Oculis Secures $277.6M Runway, Phase 3 Data Readout Set for June 2026
OCS•Oculis reported $277.6 million cash and short-term investments as of March 31, 2026, supporting operations into the second half of 2029. The company completed last patient last visit in both DIAMOND Phase 3 trials for OCS-01 with data readout due June 2026 and advanced Licaminlimab and Privosegtor regulatory milestones.
1. Strong Cash Position
Oculis held $277.6 million in cash, cash equivalents and short-term investments as of March 31, 2026, securing funding through the second half of 2029 to support its late-stage clinical programs.
2. OCS-01 Phase 3 Progress
The company completed last patient last visit in both DIAMOND Phase 3 trials for OCS-01 in diabetic macular edema, with topline results expected in June 2026 and an NDA submission planned for Q4 2026 if data are positive.
3. Licaminlimab Precision Medicine Trial
Licaminlimab’s PREDICT-1 trial is actively recruiting sites to validate genotype-driven efficacy in dry eye disease, building on Phase 2 data showing 5- to 7-fold improvements in key signs and symptoms.
4. Privosegtor SPA and PRIME Designations
Privosegtor received a Special Protocol Assessment from the FDA for its PIONEER-1 trial in optic neuritis and PRIME designation from the EMA, paving a clear regulatory pathway toward NDA submission upon successful trial outcomes.
